Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 04/24 04:00:00 pm
480.09 USD   +0.00%
04/10 REGENERON PHARM : to Report First Quarter 2015 Financial and Operati..
04/07 NASDAQ 100 MOVE : Viab, regn
03/27DJREGENERON PHARM : Correction on March 25 Regeneron Story
News SummaryMost relevantAll newsSector news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
   By Melodie Warner 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at

Subscribe to WSJ:

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
React to this article
04/10 REGENERON PHARMACEUTICALS : to Report First Quarter 2015 Financial and Operating..
04/07 NASDAQ 100 MOVERS : Viab, regn
04/01 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Receives FDA Approval f..
03/27DJREGENERON PHARMACEUTICALS : Correction on March 25 Regeneron Story
03/26DJREGENERON PHARMACEUTICALS : Correction to Headline on Wednesday's Regeneron Stor..
03/26 SANOFI : and Regeneron Release 18-Month Results of Odyssey Long Term Trial with ..
03/25DJRegeneron Wins Expanded Approval for Eye Drug Eylea
03/25 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives FDA Approval..
03/23 REGENERON PHARMACEUTICALS INC FILES (8-K) Disclosing Entry into a Material De..
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes